NovoCure (NVCR) News Today

NovoCure (NASDAQ:NVCR) Trading Down 3.9% on Analyst Downgrade

Wells Fargo & Company cut their price objective on shares of NovoCure from $42.00 to $40.00 and set an "overweight" rating for the company in a report on Friday.

HC Wainwright raised their price target on shares of NovoCure from $22.00 to $24.00 and gave the stock a "neutral" rating in a research report on Friday.

Mitsubishi UFJ Trust & Banking Corp decreased its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 22.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,261 shares of the medical equipment provider's stoc

BNP Paribas Financial Markets cut its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 75.1% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 37,179 shares of the medical equipment provider's stock after selling 112,385 sh

SG Americas Securities LLC grew its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 57.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 359,518 shares of the medical equipment provide

NovoCure (NASDAQ:NVCR) Trading 4.1% Higher

NovoCure (NASDAQ:NVCR) Trading Down 4.6%

Baillie Gifford & Co. trimmed its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 58.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,990,375 shares of the medical equipment provider's stock after selling 2,849,766 sha

Vanguard Group Inc. lifted its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,759,098 shares of the medical equipment provider's stock after bu

Evercore ISI increased their target price on shares of NovoCure from $14.50 to $20.00 and gave the stock an "in-line" rating in a research note on Tuesday.

NovoCure (NASDAQ:NVCR) Stock Price Down 8.2%

Invenomic Capital Management LP acquired a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 433,951 shares of the medical equipment provider's stock, valued at appr

Hsbc Holdings PLC increased its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 177.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 100,459 shares of the medical equipment provider'

Capital World Investors lowered its stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 63.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,276,996 shares of the medical equipment provider's stock after selling 5,601,735 shares during t

Capital International Investors lowered its position in NovoCure Limited (NASDAQ:NVCR - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,861,871 shares of the medical equipment provider's stock after s

NovoCure Limited (NASDAQ:NVCR - Get Free Report) Director W Anthony Vernon sold 964 shares of the firm's stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $23.89, for a total value of $23,029.96. Following the completion of the transaction, the director now owns 164,833 shares of the company's stock, valued at $3,937,860.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NovoCure (NASDAQ:NVCR) Shares Down 4%

NovoCure Limited (NASDAQ:NVCR - Free Report) - Wedbush boosted their Q2 2024 earnings estimates for shares of NovoCure in a research report issued to clients and investors on Monday, June 3rd. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will post earnings per

Rhenman & Partners Asset Management AB bought a new position in NovoCure Limited (NASDAQ:NVCR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 160,000 shares of the medical equipment provider's stock, valued a

Wedbush reiterated an "outperform" rating and set a $24.00 price target (up previously from $21.00) on shares of NovoCure in a research report on Monday.

NovoCure (NASDAQ:NVCR) Trading 8.4% Higher

NovoCure (NASDAQ:NVCR) Trading Down 6.2%

Ontario Teachers Pension Plan Board acquired a new position in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 83,218 shares of the medical equipmen

Trexquant Investment LP lifted its holdings in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) by 240.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 226,320 shares of the medical equi

NovoCure (NASDAQ:NVCR) Trading Down 5.9%

NovoCure (NASDAQ:NVCR) Trading Up 8%

Jump Financial LLC bought a new stake in NovoCure Limited (NASDAQ:NVCR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 103,624 shares of the medical equipment provider's stock, valued at approximately $1,547,000. Jump Financial LLC owned a

NovoCure (NASDAQ:NVCR) Trading Up 7.6%

NovoCure (NASDAQ:NVCR - Get Free Report) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. NovoCure had a negative net margin of 40.65% and a negative return on equity of 51.63%. The company had revenue of $138.50 million during the quarter, compared to analysts' expectations of $131.44 million. During the same quarter in the previous year, the business posted ($0.50) EPS. The firm's revenue was up 13.3% on a year-over-year basis.

NovoCure (NASDAQ:NVCR) Trading Up 10.5%

Wedbush restated a "neutral" rating and issued a $21.00 price target on shares of NovoCure in a research note on Thursday.

HC Wainwright lowered their price target on NovoCure from $24.00 to $22.00 and set a "neutral" rating for the company in a report on Thursday.